Search Results

Genentech’s latest layoffs are the second round of workforce reductions this year, following the company’s announcement in April that it was letting go around 3% of employees.

The unit’s closure comes as Genentech’s parent Roche rethinks its cancer business, an effort that has included the discontinuation of three early-stage candidates and a T-cell partnership with Adaptimmune.

Sangamo Therapeutics announced Tuesday it secured an exclusive licensing agreement with Roche’s Genentech, which is paying $50 million in near-term upfront fees and milestone payments to develop novel genomic medicines for neurodegenerative diseases.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s New Drug Application and granted Priority Review to inavolisib, an investigational oral therapy, in combination with palbociclib and fulvestrant.

Genentech, a member of the Roche Group, announced new 5-year data confirming the sustained efficacy and safety profile of Evrysdi® in children with Type 1 spinal muscular atrophy from the open-label extension of the pivotal FIREFISH study.

Genentech, a member of the Roche Group, announced statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi® in combination with gemcitabine and oxaliplatin versus Rituxan® in combination with GemOx for people with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy.

Roche’s subsidiary Genentech has successfully expanded the label of Alecensa to include the adjuvant treatment of anaplastic lymphoma kinase-positive, early-stage non-small cell lung cancer following resection.

Genentech, a member of the Roche Group, announced the Phase III STARGLO study met its primary endpoint of overall survival.